







an Open Access Journal by MDPI

# **Cancer Immunotherapy: Recent Advances and Prospects**

Guest Editors:

Prof. Dr. Il-Kang Na

### Dr. Antonia Busse

Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany

Deadline for manuscript submissions:

closed (30 September 2022)

# **Message from the Guest Editors**

Dear Colleagues,

In the era of emerging cancer immunotherapy, new challenges have arisen due to treatment-induced resistance mechanisms on the tumor side and alterations of innate and adaptive patients' immune systems. Each cancer-specific therapy as well as each immunotherapy results in dynamic tumor immune interaction. With a better understanding of these interactions, not only novel combination therapies but also smart sequencing strategies can be developed.

This Special Issue aims to publish research articles, reviews, and perspectives that concentrate on clinical/translational cancer immunotherapy, including in vitro and in vivo studies about novel immunotherapeutic approaches, therapy-induced immunomodulation and immunotherapy biomarkers.













an Open Access Journal by MDPI

## **Editor-in-Chief**

#### Prof. Dr. Maurizio Battino

Department of Odontostomatologic and Specialized Clinical Sciences, Sez-Biochimica, Faculty of Medicine, Università Politecnica delle Marche, Via Ranieri 65, 60100 Ancona, Italy

# Message from the Editor-in-Chief

The International Journal of Molecular Sciences (*IJMS*, ISSN 1422-0067) is an open access journal, which was established in 2000. The journal aims to provide a forum for scholarly research on a range of topics, including biochemistry, molecular and cell biology, molecular biophysics, molecular medicine, and all aspects of molecular research in chemistry. *IJMS* publishes both original research and review articles, and regularly publishes special issues to highlight advances at the cutting edge of research. We invite you to read recent articles published in *IJMS* and consider publishing your next paper with us.

### **Author Benefits**

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, MEDLINE, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Inorganic Chemistry)

## **Contact Us**